ABSTRACT -Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme that oxidizes acetaldehyde. Approximately 45% of Chinese and Japanese individuals are inactive ALDH2 phenotype; acute acetaldehyde toxicity has not been evaluated in these populations. We compared the acute acetaldehyde toxicity between wild-type (Aldh2+/+) and Aldh2-inactive transgenic (Aldh2−/−) mice who were administered an intraperitoneal (ip) injection of a single dose of acetaldehyde. This comparison was made based on the LD 50 values of acetaldehyde and the symptoms following the ip injection. Blood acetaldehyde level was measured in the 400 mg/kg dose group. Immediately after administration of acetaldehyde, the mice exhibited hypoactivity and staggering gait. Subsequently, symptoms such as pale skin, prone position, coma, and abnormal deep respiration were observed. In cases of death, dyspnea, wheezing, and hypothermia were observed from 15 to 30 min after the administration. In cases of survival, crouching, bradypnea, flushing and piloerection were observed. Significant latency of symptom recovery was found in the Aldh2+/− mice as compared with the Aldh2+/+ mice; however, no statistical difference was observed in the acetaldehyde LD 50 values. This might be attributable to the absence of a significant difference in the blood acetaldehyde concentrations in both mice during the first 0 −15 min following administration; however, acetaldehyde elimination delay was observed in the Aldh2−/− mice as compared with the Aldh2+/+ mice. Acetaldehyde toxicity difference was observed between the Aldh2+/+ and Aldh2−/− mice; however, no difference in acetaldehyde lethality was observed by administration of a single dose of an ip acetaldehyde injection.
INTRODUCTION
Acetaldehyde is widely produced as an intermediary product of alcohol, acetic acid, certain esters and a number of other chemicals in ethylene and alcohol fermentation plants; it is also present in tobacco smoke (IPCS, 1995) . Acetaldehyde is rapidly metabolized to acetic acid by aldehyde dehydrogenase (ALDH; Brein and Loomis, 1983) . ALDH is better known as one of the enzymes involved in the ethanol metabolizing process. Ingested ethanol is oxidized by cytosolic class I alcohol dehydrogenase 2 (ADH2) to acetaldehyde, which is further oxidized by mitochondrial aldehyde dehydrogenase 2 (ALDH2) to produce acetate. More than 95% of ethanol-derived acetaldehyde is oxidized by the liver mitochondrial ALDH (ALDH2) (Eriksson, 1977 , Isse et al., 2005 .
A high sensitivity (i.e., facial flushing, increase in pulse rate, elevation of blood acetaldehyde level, low alcohol tolerance) caused by ethanol-derived acetaldehyde is more commonly observed in Asians than Caucasians (Wolff, 1972) . This sensitivity in Asians is associated with a severe deficiency in ALDH2 activity, which is caused by a point mutation involving a G→A transition at nt 1510, resulting in a Glu→Lys substitution in the protein at position 487 (Yoshida et al., 1984) . ALDH2 is an allosteric tetrameric enzyme, and the ALDH2 tetramer containing inactivated monomers that are derived from the G→A transition at nt 1510 do not show an enzymatic activity (Weiner et al., 2001) . Thus, both heterozygotes and homozygotes of this ALDH2 genotype appear as inactive ALDH2 phenotype.
There are more than 1.3 × 10 9 (billion) Chinese and Japanese in the world. Most of the ALDH2-inactive individuals are distributed in these populations, and it is estimated that approximately 45% of the people in these populations are ALDH2-inactive (Dandre et al., 1995; Goddele, 1992; Matsuo et al., 2001; Mizoi et al., 1994; Novoradovsky et al., 1995) . Using pharmacokinetic-Monte Carlo simulation, Ginsberg et al. (2002) carried out the population risk assessment of internal acetaldehyde exposure due to ethanol consumption. Ethanol consumption enabled the determination of this risk assessment. Exposure to acetaldehyde is not only due to ethanol consumption but also due to the use of acetaldehyde in industrial and household materials. ALDH2-inactive individuals were estimated to be at a higher risk of toxicity due to a higher internal exposure to acetaldehyde. However, except for ethanol consumption, no data is available on accidental exposure to acetaldehyde or evidence of acetaldehyde toxicity in ALDH2-inactive individuals. Thus, we generated Aldh2 gene targeting mice that had null Aldh2 activity (Kitagawa et al., 2000) in order to directly elucidate the acetaldehyde toxicity differences between the ALDH2-inactive individuals and wild-type-ALDH2 individuals.
Under the large dose of acetaldehyde exposure, other enzymes which have high Km for acetaldehyde might effectively affect acetaldehyde metabolisms except Aldh2, and acetaldehyde adducts also might effectively affect acetaldehyde eliminations. These possible acetaldehyde elimination pathways are qualitative information, but there is no quantitative information. There is also no in vivo data for acetaldehyde acute exposure on ALDH2-inactive individuals. Thus it is still unknown whether the difference of Aldh2 activity influences acetaldehyde toxicity and eliminations, or not.
In this study, to evaluate dose-dependent acetaldehyde toxicity differences, acute toxicity that was produced by the administration of an intraperitoneal (ip) acetaldehyde injection and blood acetaldehyde levels were analyzed in the Aldh2+/+ and Aldh2−/− mice. This study is for hazard information about acetaldehyde acute exposure of ALDH2-inactive individuals, and is preliminary research for chronic acetaldehyde inhalation of ALDH2-inactive individuals.
MATERIALS AND METHODS

Drugs
Acetaldehyde (SUPELCO, Lot#LB08892, Bellefonte, PA) diluted to 5.0% with 0.9% saline was used for the injections. The acetaldehyde solution and the blood acetaldehyde concentration measurement were performed in the University of Occupational and Environmental Health (UOEH). The concentration of acetaldehyde for the injection was measured before and after the experiment and was observed to be 5.01 to 4.88% within ± 5.0% of the variability.
Animals
C57BL/6J Aldh2 tm1kaw /Aldh2 tm1kaw (Aldh2−/−) mice (Kitagawa et al., 2000; Isse et al., 2002) that were maintained with a C57BL/6J strain, and were backcrossed with the C57BL/6J strain for more than 10 generations were used for the experiments at the animal center of the UOEH. The C57BL/6J strain (Charles River Japan, Yokohama, Japan) that was used for the backcross strain served as the wild-type mice (Aldh2+/+). Animals maintained specific pathogenfree condition. Animals for the acetaldehyde acute toxicity test were brought to Panapharm Laboratories (Kumamoto, Japan) and were quarantined for at least one week to adjust to the new environment. During the quarantine period, general conditions were monitored, the body weight of the animals was measured, and no abnormalities were found. One day before the administration of the injection, we selected animals from each group by the contentious randomly. All the animals were included in the study once they were 5 weeks old. The body weight of the Aldh2+/+ and Aldh2−/− mice were as follows: male, 18.7 ± 0.8 g; female, 16.2 ± 0.7 g; and male, 20.4 ± 1.4 g; female, 16.9 ± 0.9 g, respectively. No significant difference in body weight was found between the Aldh2 genotypes by the MannWhitney test. The animal house was maintained at 24 ± 2°C, 55 ± 10% humidity, 12-hr dark-light cycle, and room air was changed 13−15 times/h. Animals were placed in polycarbonate cages (W 215 × H 140 × D 320 mm) with 2−3 animals/cage. Normal rodent chow (CRF-1, Oriental Yeast Industry, Japan) was used. The animal cages, floor beds, and rodent chow were used after autoclaving. Animal cages were replaced twice every week. The animal room was cleaned every day. All the animals were treated in accordance with the guidelines of the Animal Welfare and Ethics Committee of the Animal Care and Experimentation, Panapharm Laboratory and the UOEH.
Experimental design of acute toxicity test
The dose of acetaldehyde for the acute toxicity test was determined by preliminary up-down LD 50 value estimation. The acetaldehyde lethalities for male and female Aldh2+/+ mice were 0/3, 2/3, and 3/3 in the 550 mg/kg, 650 mg/kg, and 700 mg/kg dose groups, respectively. The acetaldehyde lethalities for male and female Aldh2−/− mice were 0/3, 3/5, and 4/5 in the 500 mg/kg, 600 mg/kg, and 650 mg/kg dose groups, respectively. Based on these results, the following doses with a formal ratio of 1.08 were determined: 700, 648, 600, 556, and 515 mg/kg. The ip injection was administered using a 0.5-mL microinjector with a 29 × 1/2-G needle. The microinjector and 5.0% acetaldehyde solution in 0.9% saline was cooled on ice. The dose volumes for each mouse were based on the body weight of the mice at the time of administration. The total number of animals involved the experiments was calculated by the following equation; Total (n) = 8 (numbers) × 5 (dose) × 2 (Aldh2 genotype) × 2 (sex) = 160. All the animals were identified by both ear punch hole and a blue, black, or red permanent pen marking.
Observation of animal symptoms in the acute toxicity test
We observed the animals for 14 d after the administration. Before the administration, at 0−1 min (JST), 1−5 min (5), 5−15 min (15), 15−30 min (30), 30−45 min (45), 45−60 min (1 hr), 2 hr, 3 hr, and 6 hr, we observed the general condition of the animals and checked their mortality status. The time periods were determined from the general conditions and symptoms exhibited during the preliminary up-down LD 50 test. The symptoms of the mice were recorded by two independent investigators. Pale skin and flushing were determined by comparing the ear, nose, foot, and tail skin color of test mice with non-test mice. Prone position and crouching was determined by the posture. Coma was determined by posture and pain reflex.
Abnormal deep respiration, bradypnea, and dyspnea were determined by the number of chest and abdomen movements. Wheezing was determined by the respiratory sounds. Hypothermia was determined by the examiner by checking the body temperature of the animals with his/her palm. Piloerection was determined by the erection of the nose hair. After the day of acetaldehyde administration, the animals were observed twice a day. Body weight was measured on the day of administration as well as 1, 3, 5, 7, 10, and 14 d after administration.
Pathological study of acute toxicity test
The animals that died during the observation period were anatomized, and liver and tissues and organs were incubated in 10% neutral formaldehyde buffer. The animals that survived were observed 14 d after the administration and scarified by bleeding under ether anesthetizations. Liver and tissues and organs were excised and incubated in 10% neutral formaldehyde buffer. Liver, kidney, heart, lung, esophagus, stomach, colon, pancreas, ovary, and testis were incubated in 10% neutral formaldehyde buffer. Paraffin blocks were prepared within 3 d after the incubation. Eleven slides of continuous sections (1.5−2 µm) were prepared and stained by hematoxylin-and eosin (H&E) staining.
Statistical analysis of mortality and symptoms
Statistical analysis was performed using a statistical software (StatView version 5.0, SAS Institute Inc., USA). Each data point shown in the tables is the mean + SD value. Probid method was used for calculating the acetaldehyde LD 50 values for the Aldh2+/+ and Aldh2−/− mice. The mortality and symptoms exhibited after each dose were compared between the Aldh2+/+ and Aldh2−/− mice by using Fisher's exact probability test for a 2 × 2 contingency table. The blood acetaldehyde level between the Aldh2+/+ and Aldh2−/− mice were compared by using unpaired ttest. Statistical significance was set at p < 0.01 and p < 0.05.
Experimental design of blood acetaldehyde measurement
The dose of 400 mg/kg was less than that at which mortality was observed and was almost the required concentration for acute toxicity tests. An ip injection was administered using a 0.5-mL microinjector with a 29 × 1/2-G needle. The microinjector and 5.0% acetaldehyde solution in 0.9% saline were cooled on ice. The dose volumes for each mouse were based on the body weight of the mice at the time of administration. There were three male animals of two strains used in the time (0, 0.5, 1, 3, 5, 10, 15, 20, 30, 60 and 120 min) . At least 200 µL blood was needed for the acetaldehyde measurement. Thus, the total number of animals involved in the experiments was calculated by the following equation; Total (n) = 3 (numbers) × 2 (Aldh2 genotype) × 11 (time) = 66. The blood acetaldehyde level was established for the ethanol administration test; however, for acetaldehyde administration, the elimination of acetaldehyde from the body was very rapid such that we were unable to measure the blood acetaldehyde concentration by using the previous sampling method and had to develop a new method. The difference in this method was that the blood was immediately collected from the decapitated trunk into liquid nitrogen-cooled plastic tubes. The sample that was mineralized on liquid nitrogen cold tube was collected faster and cooler below the acetaldehyde boiling point than in the previous method.
Acetaldehyde Concentration Measurement
The iced blood was transferred into ice-cold 0.6 N perchloric acid solution (PCA). PCA solutions with the sample were centrifuged, and 0.5 mL of the sputum was applied to gas tight vials with caps for analysis. Acetaldehyde measurement was performed according to the procedure previously described (Isse et al., 2002 ) using a Hewlett-Packard headspace sampler (HP7694, Wilmington, DE), Hewlett-Packard gas chromatograph (HP6890, Wilmington, DE) connected to a mass spectrometer (JOEL JMS-BU20, Tokyo), and a 60 m × 0.25 mm inner diameter AQUATIC capillary column (GL Sciences, Tokyo) with a 1.0-µm film thickness. The split ratio of the carrier gas (helium) was set at 20:1 and mass spectrometry analysis was carried out using electron impact ionization at 300 eV. The mass spectrum of acetaldehyde displayed major ions at m/z 44, 43, and 29. Acetaldehyde was determined by a selected ion monitoring method at m/z 43 and 29. The detection limit was determined by S/N = 2.5, and the quantization limit was determined by S/N = 6.0.
RESULTS
Mortality
The numbers of deaths are shown in Table 1 . The LD 50 value of a single ip injection of acetaldehyde was 602 mg/kg (95% relative dose, 577−624 mg/kg) and 598 mg/kg (95% relative dose, 575−625 mg/kg) in male and female Aldh2+/+ mice, respectively. The acetaldehyde LD 50 values were 567 mg/kg (95% relative dose, 545−589 mg/kg) and 587 mg/kg (95% relative dose, 564−616 mg/kg) in male and female, Aldh2−/− mice, respectively. No significant difference was observed in mortality between the Aldh2+/+ and Aldh2−/− mice as determined by Fisher's exact probability test for a 2 × 2 contingency table.
General observations of the symptoms in the acute toxicity test
Same types of symptoms were observed in both the Aldh2+/+ and Aldh2−/− mice and/or male and female mice. The frequency of the symptoms and their period of appearance differed among the genotype, sex, and dose groups (Fig. 1, Tables 2, 3 , 4, 5, and 6). The number of symptoms increased in a dose-dependent manner (Fig.1) . Hypoactivity and staggering gait were observed immediately after the administration of acetaldehyde. Pale skin, prone position, coma and abnormal deep respiration were observed 5 min after the administration of acetaldehyde. Cases of death were observed from 15 to 30 min after the administration of acetaldehyde. In cases of death, dyspnea, wheezing, and hypothermia were observed. In cases of survival, crouching, bradypnea, flushing, and piloerection were observed from 45 min to 120 min after the administration of acetaldehyde. All the symptoms disappeared after 1 to 2 hr following the administration of acetaldehyde. No animal death was observed 2 hr after the administration of acetaldehyde.
The Aldh2−/− mice showed significantly latency of appearance of the recovery symptoms as compared with the Aldh2+/+ mice (Tables 2, 3 , 4, 5, and 6). The typical differences in symptoms are shown in Fig. 2 . The number of symptoms increased in a dose-dependent manner; however, the differences observed in the symptoms disappeared in a dose-dependent manner (Tables 2, 3 , 4, 5, and 6).
Body weight change
The Aldh2+/+ and Aldh2−/− male and female mice showed a decrease in body weight after the administration of acetaldehyde; however, they also showed an increase in body weight from 3 d after the administration of acetaldehyde (Fig. 3) .
Pathological study of acute toxicity test
In living Aldh2+/+ mice, no abnormalities were observed, except expansion of the renal pelvis, which was observed in one male of the 700 mg/kg dose group. Further, in living Aldh2−/− mice as well, no abnormalities were observed except expansion of the renal pelvis, which was observed in one male in each of the 600 and 700 mg/kg dose groups. These expansions of the renal pelvis were considered to be non-specific and no toxicological abnormalities were observed. In all cases of survival, no abnormalities were found with the naked eye and microscopic observations.
Blood acetaldehyde concentration
The 400 mg/kg dose equals 9080 µmole/kg. The peak blood acetaldehyde concentration was recorded between 1 to 3 min after the administration of acetaldehyde. Until 10 min after the administration, blood acetaldehyde concentrations were almost the same in the Aldh2+/+ and Aldh2−/− mice; however, a significant delay in acetaldehyde elimination was found in the Aldh2−/− mice as compared with the Aldh2+/+ mice ( Table 7) .
DISCUSSION
To compare the difference in toxicity between the Aldh2+/+ and Aldh2−/− mice, we first performed the Table 1 . Number of deaths due to acetaldehyde in the Aldh2+/+ and Aldh2−/− mice. Table 6 . Number of abnormal symptoms produced by the administration of a 700 mg/kg acetaldehyde injection. acute toxicity test. However, a few studies showed that acute acetaldehyde toxicity could be induced by injections. Skog (1950) reported that the mouse acetaldehyde LD 50 by a subcutaneous injection was 0.56 g/kg body weight and that the rat acetaldehyde LD 50 was 0.64 g/kg body weight. Truitt and Walsh (1971) reported that the mouse acetaldehyde LD 50 by ip injection was 500 mg/kg body weight, and effective dose 50% (ED 50 ) of sleeping time was 275 mg/kg body weight; however, no statistical analysis was described and the determination of sleeping time was unclear. O'shea and Kaufman (1979) reported that the mouse acetaldehyde LD 50 by intravenous injection was 5.3% (v/v) acetaldehyde in saline, which was administered as a dose of 0.1 ml/25 g body weight (i.e., 165 mg/kg body weight). Almost all deaths occurred within 30 min after the injections, and the survivors appeared to have recovered after that time (Truitt and Walsh, 1971; Skog, 1950) . It was also reported that after a few minutes the animals become unconscious since the anesthesia lasted from 10 to 30 min. Other recorded symptoms were lack of activity, sedation, ataxia and gasping (Truitt and Walsh, 1971; Skog, 1950) . On account of the limited information on dose-dependent acetaldehyde toxicity, the revaluation of acetaldehyde acute toxicity was deemed necessary by preliminary updown estimation, and hence we performed the dosedependent test. Major findings in this study were that the acetaldehyde mortality values were similar for the Aldh2+/+ and the Aldh2−/− mice, and toxic symptoms were delayed in the Aldh2−/− mice. The acetaldehyde mortality values in the Aldh2+/+ and Aldh2−/− mice were found to be the same; this would be attributed to the similar levels of acetaldehyde in the blood at the peak and at 0−5 min after administration. The reason for the difference in the symptoms of acetaldehyde toxicity was that the acetaldehyde elimination was delayed in the Aldh2−/− mice 15 min after administration. Acetaldehyde forms protein adducts (Tuma et al., 1991) , nucleotides (Noori and Hou, 2001) , phospholipids (Kenney, 1982) , epinephrine (Davis and Walsh, 1970) , (0, 0.5, 1, 3, 5, 10, 15, 20, 30, 60 and 120 min) . The total number of animals involved in the experiments was calculated by the following equation; Total (n) = 3 (numbers) × 2 (Aldh2 genotype) × 11 (time) = 66., ND; under the detection limit, SD; standard deviation, *; p<0.05, **; p<0.01 by unpaired t-test. Vol. 30 No. 4 and dopamine (Sjoquist et al., 1982) in the body. Some substrates bind to acetaldehyde and become Schiff bases; others form condensation compounds with acetaldehyde. Although there is no dose-dependent literature on acetaldehyde and the adducts it forms in the body, acetaldehyde is believed to be a highly reactive compound and forms a considerable amount of adducts in the body. Under the large dose of acetaldehyde exposure, Aldh1, Aldh3 and other enzymes which have high Km for acetaldehyde might also effectively affect acetaldehyde metabolisms except Aldh2. These adduct formation and metabolisms might cause the same blood acetaldehyde peak and blood level during the distribution phase in the Aldh2+/+ and Aldh2−/− mice.
We could not collect enough amount of blood from the 515 mg/kg or more higher dose groups constantly during the severe symptom in the preliminary experiment. It is estimated that circulatory defects disturb the sampling. Then we performed a 400 mg/kg dose of acetaldehyde for the measurement of blood acetaldehyde level. A coma lasting within a few minutes was observed in both in the Aldh2+/+ and Aldh2− /− mice. The time period of the coma seemed longer in the Aldh2−/− than in the Aldh2+/+ mice, but we could not find a significant difference between these genotypes. Another toxic symptoms were not observed.
It is now clear that with the administration of an acute ip injection of acetaldehyde, the aldehyde dehydrogenase 2 activity affects the toxic symptoms and not mortality. Blood acetaldehyde levels support these phenomena in the Aldh2+/+ and Aldh2−/− mice. At the first periods, blood acetaldehyde level in the Aldh2+/+ mice and the Aldh2−/− mice was almost the same. Death and other severe symptoms might be affected by Cmax or these same blood acetaldehyde levels. The lasting blood acetaldehyde levels were higher in the Aldh2−/− mice than the Aldh2+/+ mice, and the Aldh2−/− mice showed significant lasting of the acetaldehyde toxic symptom than did the Aldh2+/+ mice. The difference of acetaldehyde toxic symptom in the lasting period might be affected by the acetaldehyde level difference or AUC difference between the Aldh2+/+ and Aldh2−/− mice. Only a small blood acetaldehyde level difference was found in the Aldh2+/+ and Aldh2−/− mice by a single-dose acetaldehyde ip injection. On the other hand, blood acetaldehyde was significantly and remarkably higher in the Aldh2−/− mice than in the Aldh2+/+ mice after ethanol gavages (Isse et al., in press ). Ethanol administration is considered to be the same as a repeat administration of acetaldehyde. Acetaldehyde inhalation could be assumed as a repeat exposure when the acetaldehyde elimination rate is slower than the absorption rate (Gehring et al., 1976) . Thus, this study suggests that aldehyde dehydrogenase 2 activities could affect the difference in acute and chronic acetaldehyde toxicity in Aldh2−/− mice.
